¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"peripheral inhibition"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • competitive inhibition
    °æÀï¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦°Ë»ç
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
  • hemagglutination-inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ
  • irreversible inhibition
    ºñ°¡¿ª¾ïÁ¦
  • immunologic inhibition
    ¸é¿ª¾ïÁ¦
  • inhibition
    ¾ïÁ¦, ÀúÁö
  • inhibition reaction
    ¾ïÁ¦¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • afferent inhibition
    µé½Å°æ¾ïÁ¦, ±¸½É¾ïÁ¦
  • agar gel precipitin inhibition test
    ¿ì¹«°Öħ°­¼Ò¾ïÁ¦°Ë»ç
  • allogenic inhibition
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • antidromic inhibition
    (¢¡recurrent inhibition) ȸ±Í¾ïÁ¦
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü
  • colony inhibition test
    ¼¼Æ÷±ºÇü¼º¾ïÁ¦°Ë»ç, Áý¶ôÇü¼º¾ïÁ¦°Ë»ç
  • competitive inhibition
    °æÀï¾ïÁ¦, °æÇÕ¾ïÁ¦
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • contact inhibition
    Á¢Ã˾ïÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • enzyme inhibition
    È¿¼Ò¾ïÁ¦
  • feedback inhibition
    µÇ¸ÔÀÓ¾ïÁ¦
  • fertility inhibition
    ¼öÅÂÀÎÀÚÀü´ÞÀúÁö
  • migration inhibition factor
    Æ÷½Ä¼¼Æ÷À̵¿ÀúÇØÀÎÀÚ
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦°Ë»ç
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • inhibition test, hemagglutination
    Ç÷±¸ÀÀÁý ¾ïÁ¦½ÃÇè, Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test, migration
    À¯ÁÖ¾ïÁ¦½ÃÇè, À¯ÁÖÀúÁö½ÃÇè
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibition(-tory) factor, macrophage migration
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ
  • inhibition, allogeneic
    µ¿Á¾ÀÌÇü¾ïÁ¦
  • inhibition, contact
    Á¢Ã˼º Áõ½Ä¾ïÁ¦
  • inhibition, fertility
    FÀÎÀÚ Àü´ÞÀúÁö, ¼öÅÂÀÎÀÚ Àü´ÞÀúÁö
  • postsynaptic inhibition
    ½Ã³³½ºÈľïÁ¦ (¡­ý­åäð¤).
  • postsynaptic inhibition
    ¿¬Á¢ÈľïÁ¦
  • presynaptic inhibition
    ½Ã³³½ºÀü¾ïÁ¦ (¡­åäð¤).
  • presynaptic inhibition
    ½Å°æÁ¢ÇÕÀü ¾ïÁ¦
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(¡­îÁò­ãËúÐ).
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(?Ëø?ËàÌ´).
  • hemagglutination inhibition antibody
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition antibody
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦Ç×ü.
  • hemagglutination inhibition reaction
    ÀûÇ÷±¸ÀÀÁý¾ïÁ¦¹ÝÀÀ.
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • immunologic inhibition
    ¸é¿ªÇÐÀû ¾ïÁ¦.
  • indirect inhibition
    °£Á¢¾ïÁ¦.
  • inhibition
    ¾ïÁ¦,±ÝÁö
  • inhibition
    ¾ïÁ¦
  • inhibition
    ¾ïÁ¦.
  • inhibition
    ¾ïÁ¦, ÀúÁö
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mixed inhibition
    È¥ÇÕÀúÇØ(ûèùêîÁúª)
  • multiple inhibition analysis
    ´ÙÁß(Òýñì)ÀúÇØ ºÐ¼®(îÁúªÝÂà°)
  • multivalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸®ÀúÇØ(îÁúª)
  • multivalent feedback inhibition
    ´Ù°¡(Òýʤ) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • noncompetitive inhibition
    ºñ°áÇÕ ÀúÇØ(ު̿ùêîÁúª)
  • parabolic inhibition
    Æ÷¹°¼±Çü(øØÚªàÊû¡) ÀúÇØ(îÁúª)
  • partial inhibition
    ºÎºÐ ÀúÇØ(Ý»ÝÂîÁúª)
  • polyvalent allosteric inhibition
    ´Ù°¡(Òýʤ) ¾Ë·Î½ºÅ׸® ÀúÇØ(îÁúª)
  • product inhibition
    »ê¹°ÀúÇØ(ß§ÚªîÁúª)
  • pseudofeedback inhibition
    À§(êÊ)µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • sequence feedback inhibition
    ¼­¿­(ßíÖª) µÇ¸ÔÀÓÀúÇØ(îÁúª)
  • substrate inhibition
    ±âÁúÀúÇØ (ÐñòõîÁúª)
  • suicide inhibition
    ÀÚ¸ê ÀúÇØ(í»ØþîÁúª)
  • total inhibition
    ÀüÀúÇØ(îïîÁúª)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PVP penicillin V potassium; peripheral vein plasma; peripheral venous pressure; polyvinylpyrrolidone; po...
LAI assay Leukocyte Adherence Inhibition assay
MIF   1) Mllerian Inhibiting Factor
  2) Migrating Inhibition Factor
TBII TSH Binding Inhibiting(= Inhibition) Immunoglobulin
AGPI agar gel precipitin inhibition
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ITIM immunoreceptor tyrosine-based inhibition motif
IR Inhibition Rate
(125)I Inhibition of
IOR Inhibition of return
ICI Intracortical inhibition
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • peripheral anterior synechia
    ÁÖº¯ ȫä ¾Õ À¯Âø
  • peripheral axon
    ¸»ÃÊ Ãà»è
  • peripheral cataract
    ÁÖº¯ ¹é³»Àå
  • peripheral chemoreceptor
    ¸»ÃÊ È­ÇÐ ¼ö¿ëü
  • peripheral circulation
    ¸»ÃÊ ¼øÈ¯
  • peripheral connection
    ¸»Ãʼº ¿¬°á
  • peripheral corneal degeneration
    ÁÖº¯ °¢¸· º¯¼º
  • peripheral cyanosis
    ¸»ÃÊ Ã»»öÁõ, ¸»Ãʼº û»öÁõ
    Á¤¸Æ Ç÷¾× ÁßÀÇ È¯¿ø Çì¸ð±Û·Îºó °úÀ×À¸·Î ÀϾ´Â û»öÁõ. ¸ð¼¼°ü ´Ü°è¿¡¼­ÀÇ ´ë·®ÀÇ »ê¼Ò ÃßÃâÀÌ ¿øÀÎÀÌ´Ù.
  • peripheral dendritic process
    ¸»ÃÊ °¡Áö µ¹±â¼º µ¹±â
  • peripheral doublet
    ÁÖÀ§ ¹Ì¼¼°ü µÎ¦
  • peripheral embolism
    ¸»ÃÊ µ¿¸Æ »öÀüÁõ
  • peripheral epilepsy
    ¸»Ãʼº °£Áú
  • peripheral fading
    ¸»´ÜºÎ ¼Ò¸ê
  • peripheral field
    ¸»ÃÊ ¿µ¿ª
  • peripheral gating
    ¸»ÃÊ °ÔÀÌÆÃ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
lymphoma, T-cell, peripheral A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (lymphoma, large-cell, immunoblastic), this group's unique features warrant separate treatment.
(12 Dec 1998)
allogeneic inhibition Inhibition or injury to allogeneic cells that occurs when lymphocytes are mixed and cultured with other cells of different genotypes in vitro.
(05 Mar 2000)
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
macrophage migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
cell migration inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated leukocytes or macrophages. Specific assays have been developed to estimate levels of migration-inhibitory factor, immune reactivity against tumour-associated antigens, and immunosuppressive effects of infectious microorganisms.
(12 Dec 1998)
central inhibition <physiology> Suppression or diminution of outgoing impulses from a reflex centre.
(05 Mar 2000)
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
migration inhibition test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á